231 S. Whisman Road
8 articles with SanBio
SanBio to Announce the Results of a Phase 2 STEMTRA Trial Regarding the Use of Regenerative Cell Medicine SB623 as a Treatment for TBI at an Annual Scientific Meeting of the American Association of Neurological Surgeons
The SanBio Group today announced its plan to make public the results of a global Phase 2 trial (Study of Modified Stem Cells in Traumatic Brain Injury, or “STEMTRA”) conducted in the US and Japan regarding the use of regenerative cell medicine SB623 as a treatment for chronic motor deficit from traumatic brain injury (TBI).
SanBio Announces Phase 2 STEMTRA Trial Using SB623 Cells for Treatment of Patients with Traumatic Brain Injury Met Primary Endpoint
The SanBio Group announces today that the Phase 2 STEMTRA trial using SB623 cells for the treatment of patients with traumatic brain injury (TBI), met its primary endpoint.
SanBio: Supplementary Information to the Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623
SanBio Co., Ltd. has agreed to enter into an equity and business alliances
SanBio: Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623
SanBio Co., Ltd. hereby announces that it has resolved to enter into an equity and business alliances
SanBio: Acquisition of a Patent Portfolio Regarding Cell Medicines Derived from Mesenchymal Stem Cells
The SanBio Group today announced the acquisition of a patent portfolio regarding cell medicines derived from mesenchymal stem cells (hereinafter the Patent Portfolio).
SanBio Company Limited announced it has concluded an agreement with Keio University School of Medicine on joint research for SB623 targeting dementia.
The Group hereby announces procurement of funds totaling ¥11,000 million upon completion of exercise of share acquisition rights with an exercise price adjustment clause issued on April 6, 2018.
SanBio's US-based Phase 1/2a Clinical Trial of SB623 for the Treatment of Chronic Motor Deficit from Ischemic Stroke Was Addressed at an Event Held by California Institute for Regenerative Medicine (CIRM)
The SanBio Groupn hereby announces that the US-based phase 1/2a clinical trial of SB623 for the treatment of chronic motor deficit from ischemic stroke